AN INVESTIGATION INTO THE ROLE OF MATRIX METALLOPROTEINASES (MMP’s) IN LOWER LIMB VASCULAR RESTENOSIS - Role of MMPs in Lower Limb Restenosis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-004876-36-GB

Enrollment

150

Registered

2005-02-15

Start date

2005-04-15

Completion date

Unknown

Last updated

2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post angioplasty and post vein graft stenosis.

Interventions

Trade Name: Periostat Product Name: Doxycycline Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients under the care of the Cambridge Vascular Unit undergoing lower limb angioplasty or infra inguinal bypass grafting. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Unable to give informed consent, Age less than 18years, Pregnancy or planned pregnancy, life expectancy less than 12months.

Design outcomes

Primary

Measure	Time frame
Main Objective: To Study therole of Matrix Mettalloproteinases (MMP) in the process of re-stenosis following angioplasty and vein bypass graft stenosis.;Secondary Objective: Usage of subantimicrobial doses of Doxycycline (20mg twice daily) to inhibit MMPs and thereby limit re-stenosis.;Primary end point(s): MMP activities in SDD versus Placebo. CRP levels. Endothelial function and re-stenosis. Arterial wall stffness and re stenosis.	—

Measure

Time frame

Main Objective: To Study therole of Matrix Mettalloproteinases (MMP) in the process of re-stenosis following angioplasty and vein bypass graft stenosis.;Secondary Objective: Usage of subantimicrobial doses of Doxycycline (20mg twice daily) to inhibit MMPs and thereby limit re-stenosis.;Primary end point(s): MMP activities in SDD versus Placebo. CRP levels. Endothelial function and re-stenosis. Arterial wall stffness and re stenosis.

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026